AOA
0.003
50%
BOC
0.575
-50%
BUY
0.003
50%
TR2
0.34
-44.3%
ENL
0.033
43.5%
BLZ
0.002
-33.3%
ALM
0.007
40%
1AD
0.003
-25%
FBR
0.004
33.3%
C7A
0.003
-25%
AAU
0.01
25%
CTN
0.003
-25%
AUR
0.02
25%
RLC
0.003
-25%
MTM
0.855
24.8%
M2M
0.013
-23.5%
LM1
0.185
23.3%
IS3
0.018
-21.7%
SPQ
0.011
22.2%
EPM
0.015
-21.1%
PHX
0.14
21.7%
NFM
0.02
-20%
NHE
0.045
21.6%
OEL
0.004
-20%
PLC
0.006
20%
FMR
0.275
-16.7%
SHN
0.02
17.6%
KOB
0.06
-16.7%
AS2
0.014
16.7%
DY6
0.115
-14.8%
SIO
0.14
16.7%
MGU
0.006
-14.3%
ATC
0.029
16%
WLD
0.012
-14.3%
RLF
0.074
15.6%
ZMM
0.006
-14.3%
IMI
0.015
15.4%
HWK
0.025
-13.8%
PTX
0.062
14.8%
NVQ
0.02
-13%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Cleo Diagnostics (ASX:COV): Bringing to market a simple blood test

Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747